Recently, novel classes of antidiabetic therapy, such as sodium-glucose cotransporter (SGLT)-2 inhibitors and glucagon-like peptide-1 receptor agonist (GLP1-RA), have shown anti-obesogenic effects, alone or in combination, and they also are able to exert beneficial effects on atherosclerosis and CVD risk [100]. The gene discussed is GLP1R; the disease is atherosclerosis.